Methods and Compositions for Treating Melanoma
AssigneeThe Wistar Institute of Anatomy and Biology
InventorsRajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
Claims9
A composition comprising a nucleic acid sequence encoding:
- (a) Xaa1-Xaa2-Leu-Xaa4-Thr-Glu-Lys-Ser-Arg-Trp-Ser-Xaa12-Xaa13-Xaa14 (SEQ ID NO:
- 4), wherein Xaa1, Xaa2, Xaa13, and Xaa14, are each independently absent, Ser, Gly, or Cys for coupling to an additional peptide or protein, and wherein amino acid Xaa4 is a substituted or unsubstituted Ile and amino acid Xaa12 is a hydrophobic amino acid;
- or
- (b) Xaa1-Xaa2-Leu-Xaa4-Thr-Glu-Lys-Ser-Arg-Trp-Ser-Xaa12-Xaa13-Xaa14 (SEQ ID NO:
- 5), wherein Xaa1, Xaa2, Xaa13, and Xaa14 are each independently absent, Ser, Gly, or Cys for coupling to an additional peptide or protein, and wherein Xaa4 is a hydrophobic amino acid and Xaa12 is a substituted or unsubstituted Gly, Val or Leu;
- (c) Xaa1-Xaa2-Leu-Xaa4-Thr-Glu-Lys-Ser-Arg-Trp-Ser-Xaa12-Xaa13-Xaa14 (SEQ ID NO:
- 6), wherein Xaa1, Xaa2, Xaa13, and Xaa14, are each independently absent, Ser, Gly, or Cys for coupling to an additional peptide or protein, and wherein Xaa4 is a substituted or unsubstituted Ile, Ala, Met or Leu, and wherein Xaa12 is a substituted or unsubstituted Gly, Ile, Val or Leu.
- (d) a peptide or polypeptide encoding a fusion peptide comprising the peptide of (a), (b) or (c) fused to a T cell peptide at either the N- or C-termini;
- or
- (e) a peptide or polypeptide encoding a fusion peptide comprising at least two copies of the same peptide of (a), (b), (c) or (d).
The composition according to claim 27, wherein the checkpoint inhibitor is CTLA4, PD1, PDL1, LAG3, ICOS, BTLA, KIR, OX40, CD27, CD40L, CD40, TIM3 or TIM334.
Dependencies are inferred from the claim text.